Sign In
Buy CNS
$70.20
-1.00 (-1.40%)
At Close: Jun 03, 2026
Cohen & Steers, Inc. (CNS) Q3 2024 Earnings Call Transcript
02:09pm, Thursday, 17'th Oct 2024
Cohen & Steers, Inc. (NYSE:CNS ) Q3 2024 Earnings Conference Call October 17, 2024 10:00 AM ET Company Participants Brian Heller - Senior Vice President and Corporate Counsel Jon Cheigh - Chief Invest
COHEN & STEERS REPORTS RESULTS FOR THIRD QUARTER 2024
04:19pm, Wednesday, 16'th Oct 2024
NEW YORK , Oct. 16, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended September 30, 2024. The earnings release along with the accompanying earnings
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
09:00am, Thursday, 10'th Oct 2024
Segment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust Access the segment here HOUSTON, TX / ACCESSWIRE / October 10, 2024 / CNS
Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)
07:42am, Thursday, 10'th Oct 2024
Neurocrine Biosciences' Ingrezza has grown into a multibillion-dollar drug, but the company's stock has underperformed the S&P 500 since 2019. Neurocrine's NBI-1117568 demonstrated encouraging Phase 2
Cohen & Steers, Inc. to Release Third Quarter 2024 Results on October 16, 2024
04:41pm, Wednesday, 09'th Oct 2024
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release third quarter 2024 results after the market closes on Wednesday, October 16, 2024. The ear
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows For September 2024
04:23pm, Tuesday, 08'th Oct 2024
NEW YORK , Oct. 8, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $91.8 billion as of September 30, 2024, an increase of $3.7 billion from
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
09:15am, Tuesday, 08'th Oct 2024
Live webcast fireside chat on Wednesday, October 16th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / October 8, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical c
Study shows the repeated long-term, as-needed use of STS101 for the acute treatment of a migraine attack demonstrated a favorable safety profile and was well tolerated. Exploratory Efficacy Endpoints
Corero Network Security Secures $6M in New Orders To Close Q3 2024
07:00am, Tuesday, 08'th Oct 2024
Total Orders for 2024 Reach $20.2 Million LONDON , Oct. 8, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, to
NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024
11:00am, Monday, 07'th Oct 2024
NeOnc's Novel Intranasal Approach to Bypassing the Blood Brain Barrier with Therapeutics for CNS Diseases Featured as Cover Page Story in Recent Edition of Pharma Tech Outlook NeOnc's Novel Intranasal
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
04:28pm, Wednesday, 02'nd Oct 2024
VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developin
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
08:03am, Tuesday, 01'st Oct 2024
CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Cohen & Steers Closed-End Funds Declare Distributions for October, November, and December 2024
06:00pm, Monday, 30'th Sep 2024
NEW YORK , Sept. 30, 2024 /PRNewswire/ -- The Boards of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for October, November, and December 2024, as summariz
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
04:00pm, Monday, 30'th Sep 2024
NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyl
Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
04:52pm, Friday, 27'th Sep 2024
NEW YORK , Sept. 27, 2024 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") with information regarding the sources o
